GH Research (GHRS) Corporate presentation summary

Pipeline and financial position

• Lead candidate GH001 targets treatment-resistant depression (TRD), postpartum depression, and bipolar II disorder, with Phase 2b completed and Phase 3 initiation planned for 2026.

• GH002, an intravenous formulation, is in preclinical and early clinical stages for psychiatric disorders.

• Cash, cash equivalents, and marketable securities totaled $267.3 million as of March 31, 2026.

Clinical trial design and efficacy

• Phase 2b trial for GH001 in TRD used a randomized, double-blind, placebo-controlled design with an open-label extension (OLE).

• GH001 achieved a placebo-adjusted mean MADRS reduction of -15.5 at Day 8 (p<0.0001), with a large effect size (Cohen's d = -2.0).

• Remission rates were 57.5% at Day 8 and 73% at 6 months among OLE completers.

• Initial remitters had a 90% remission rate at 6 months; 43.5% of initial non-remitters achieved remission by 6 months.

• Efficacy was reproducible in both double-blind and OLE phases.

Comparison to other therapies

• GH001 showed greater MADRS reduction and higher remission rates than Spravato and oral antidepressants in indirect comparisons.

• Median psychoactive experience duration was 11 minutes for GH001, significantly shorter than Spravato (1.5 hours) and COMP360 (6-8 hours).

• GH001 required 83% fewer treatment visits over 6 months compared to Spravato (4 vs. 23 visits).

• No additional psychotherapy or therapist visits were needed with GH001.